Categories
Filter by Topics
ALK aplastic anemia AA Autoimmune Disorder B-cell lymphoma Biology of neoplasia Biomarkers Bladder Cancer Brain Breast Cancer CD3 Cells Cerebrospinal Fluid clinical trial cold tumor Colorectal cancer Comparison study CXCL12 Cytokines Developmental Immunotherapy Developmental Therapeutics Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Encephalophy EPCORE NHL-1 ERBB3 FFPE Gene Expression Profiling Genetic Polymorphism Heart Histone Deacetylase Inhibitors hot tumor HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTP Immune Checkpoint Inhibitors Immune Response Immune-related Colitis Immuno-Oncology IMMUNOSARC Immunotherapy IOA- 244 Kidney Liposarcoma Liver Lung lymphoma Lymphoma Melanoma Microenvironment miRNA Molecular Characterization Nash and Fibrosis Natural Killer Cells Nestin+ Neurologic non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL OBP Oesophageal Adenocarcinoma PanB Pancreas pancreatic ductal adenocarcinoma PDAC Parkinson's Disease Pathway Analysis PI3K inhibitors PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate qNPA qPCR Radioimmunotherapy Rheumatoid Arthritis Sarcoma Serum Signatures soft tissue sarcoma Sub-typing Survival plots T cells Thymic Carcinoma Tislelizumab TME Transplantation Treatment Outcome Treatment Targets Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Zanubrutinlb2022
SABCS 2022: PD-17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials.
Prognostic Value of EZH2 Expression for Immunotherapy-based Schemes in Advanced Soft-tissue Sarcoma
- Categories
- Posters
Biomarkers for Response to Immunotherapy in Triple-Negative Breast Cancer - Differences Between Survival and pCR Biomarkers
- Categories
- Posters
DLBCL Cell of Origin Typing and Whole Transcriptome Analysis using Single Slides with HTG EdgeSeq
2021
Biological processes associated with the efficacy of sunitinib plus nivolumab in soft tissue sarcoma: correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups - poster
Lacerenza, S., et al., Biological processes associated with the efficacy of sunitinib plus nivolumab in soft tissue sarcoma: correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
- Categories
- Posters
Safety and efficacy of CD3-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and Other Non-Hodgkin's B-cell Lymphomas - a Phase 2 Study
Levy, M. Y., et al. Safety and efficacy of CD3-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and Other Non-Hodgkin's B-cell Lymphomas - a Phase 2 Study. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021
- Categories
- Posters
Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure
Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021
Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis.
Benitez, J. C., et al. Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis. J Clin Oncol 39, 2021 (suppl 15; abstr 8575); 10.1200/JCO.2021.39.15_suppl.8575
- Categories
- Posters
CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.
Pascual, J., et al. CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. J Clin Oncol 39, 2021 (suppl 15; abstr 1014) DOI: 10.1200/JCO.2021.39.15_suppl.1014
- Categories
- Posters
Correlate with Improvement in Disease Activity in Patients with Rheumatoid Arthritis on Tumour Necrosis Factor Inhibitors. Annals of the Rheumatic Diseases
David, T., et al. MiRNAs Correlate with Improvement in Disease Activity in Patients with Rheumatoid Arthritis on Tumour Necrosis Factor Inihibitors. Annals of the Rheumatic Diseases 2021;80:409; Poster 0357
- Categories
- Posters
Page last updated March 13, 2023